ASRS 2024: Clinical characterisation of HK1 associated with retinitis pigmentosa

News
Video

At this year's ASRS meeting, Patrick C. Staropoli, MD, discussed his presentation about autosomal dominant pericentral retinitis pigmentosa

Patrick C. Staropoli, MD, caught up with the Eye Care Network at this year's ASRS meeting. He detailed his presentation on the clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa.

Editor's note: The below transcript has been lightly edited for clarity.

Patrick C. Staropoli, MD: Hi, my name is Patrick Staropoli, an associate physician at Retina Consultants of Texas. I am really excited to be out here in Sweden for ASRS. I just finished my presentation a little while ago. Today, I got to speak about HK1 associated retinitis pigmentosa. It's an autosomal dominant type of retinitis pigmentosa.

What we wanted to do is to sort of characterise all of the clinical features of this disease, because even though it's been researched and described extensively, the papers that are out there in literature really don't have a clear pattern or consensus on what this looks like clinically. So, what we found in our series of patients in our practice is about 30 patients, 60 eyes, 22 unrelated families. And there's a very distinct pattern that you can see on the autofluorescence, where basically it's just the posterior pole, for the most part that is affected. There's a hyperautofluorescent ring that goes around the macula and the arcades. And there's also more of involvement on the nasal side of the periphery rather than the temporal side. So, it's a really distinct pattern. If you pick it up in clinic, your light bulb immediately should go off...this could be HK1-associated retinitis pigmentosa. It's usually inherited in autosomal, dominant fashion. So it does have implications for families.

That was pretty much what we tried to put together today, and make people more aware of it. And one of the other things that's really interesting about this disease process is that the mutation that is most frequent in HK1 actually doesn't affect the functional domain of the protein. So, HK1 is the first step in glycolysis. And even though the protein still functions normally, the question still comes up, "Well, how is this causing damage to the retina?" And as of this point in time, no one really knows for sure. HK1 is known to interact with other proteins that affect apoptosis. And so it's possible that 1 of these peripheral changes is affecting its ability to interact with these other proteins and that leads to unregulated apoptosis, but more research will help us figure that out.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.